Non Muscle Invasive Bladder Cancer (NMIBC) - Pipeline Insight, 2020

Publisher Name :
Date: 24-Sep-2020
No. of pages: 90
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Non Muscle Invasive Bladder Cancer (NMIBC)- Pipeline Insight, 2020," report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Non-Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Non Muscle Invasive Bladder Cancer Understanding

Non Muscle Invasive Bladder Cancer: Overview

NMIBC is defined as a superficial neoplasia confined to the mucosa, (including Ta which is a noninvasive papillary carcinoma and carcinoma in situ (CIS), which is flat and non-papillary) or lamina propria (T1) based on the American Joint Committee on Cancer (AJCC) staging system, also known as the tumor node metastases (TNM) classification. Ta accounts for most NMIBC (60%), whereas T1 and Tis (CIS) account for 30% and 10%, respectively.

Symptoms

Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:

- Hematuria (blood in the urine) - the most common symptom, often without pain

- Frequent and urgent urination

- Pain when urine passes

- Pain in lower abdomen

- Back pain

Diagnosis

The following tests may be done to determine bladder cancer:

- Urine cytology: The color and content of the urine will be checked. This test will also look at body cells under a microscope.to test for cancer cells.

- Blood tests: A comprehensive metabolic panel (CMP), which includes kidney and liver function tests

- A. Computerized tomography scan (also known as CT or CAT scans) with a bladder scope "cystoscopy" are often good enough to diagnose bladder cancer.

- Cystoscopy: A doctor will use a thin tube that has a light and camera at the end of it (cystoscope) to pass through the urethra into the bladder.

Treatment

The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy. Pembrolizumab is approved for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy

Non Muscle Invasive Bladder Cancer Emerging Drugs Chapters

This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non Muscle Invasive Bladder Cancer Emerging Drugs

- Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. It is currently in phase III stage of development.

- UGN-102: UroGen Pharma

UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC.Administered locally via standard catheters, UGN-102 is designed to fill and conform to the anatomy of the bladder and dwell for a period of several hours before being excreted via normal urine flow. UroGen has completed enrollment in a phase 2b study to further investigate UGN-102 for the treatment of intermediate-risk low-grade NMIBC.

Further product details are provided in the report……..

Non Muscle Invasive Bladder Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Non-Muscle Invasive Bladder Cancer

There are approx. 25+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. phase III include, Bristol-Myers Squibb/Ono Pharmaceuticals.

- Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravitreal

- Subretinal

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non Muscle Invasive Bladder Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non Muscle Invasive Bladder Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.

- In July 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical had signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.

- In April 2020, UroGen Pharma announced positive interim data analysis of UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). These data were featured in a late-breaking abstract published in the April Supplement to The Journal of Urology. The detailed results presentation will be available online via the American Urological Association (AUA) in mid-May 2020.

Non Muscle Invasive Bladder Cancer Report Insights

- Non Muscle Invasive Bladder Cancer Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Non Muscle Invasive Bladder Cancer Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Non Muscle Invasive Bladder Cancer drugs?

- How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non Muscle Invasive Bladder Cancer?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Viventia Bio

- Viralytics

- Vaxiion Therapeutics

- UroGen Pharma Ltd.

- EMD Serono

- AstraZeneca

- Hoffmann-La Roche

- Theralase Inc

- Telormedix

- Taris Biomedica

- Spectrum Pharmaceuticals

- Incyte Corporation

- Rapamycin Holding

- Pfizer

- NanOlogy

- Merck Sharp & Dohme Corp.

- Lipac Oncology

- Jiangsu Yahong Meditech Co.,Ltd.

- Janssen Research & Development, LLC

- Hoffmann-La Roche

- Handok

- Hamlet Pharma AB

- Halozyme Therapeutics

- Apices Soluciones

- FKD Therapies

- H3 Biomedicine Inc.

- CG Oncology, Inc.

- Bioniche Life Sciences Inc.

- BioCis Pharma

- Asieris Pharmaceutical

- Archivel Farma

- Altor BioScience

- Aadi,

Key Products

- Vicinium

- Instiladrin

- PF-06801591

- Atezolizumab

- APL 1202

- Imfinzi

- Opdivo

- Apaziquone

- CG0070

- Inodiftagene vixteplasmid

- Balversa

- LiPax (paclitaxel)

- Pemigatinib

- TLD 1433

- ALT-803

- Lenalidomide

- UGN-102

- ABI-009

- ALT-801

- Alpha1H

- NanoDoce

- HS-410

- Avelumab

- BGJ398

- UGN-201

- TAR 200

- E7766

- VAX014

- Cavatak

- UGN-302

- ATX 101

- TL-532

- Bladder Cancer Program

Non Muscle Invasive Bladder Cancer (NMIBC) - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Non Muscle Invasive Bladder Cancer: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Non Muscle Invasive Bladder Cancer - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* Non Muscle Invasive Bladder Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends
Non Muscle Invasive Bladder Cancer Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
* Comparative Analysis
Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals
* Product Description
* Research and Development
* Product Development Activities
Mid Stage Products (Phase II)
* Comparative Analysis
UGN-102: UroGen Pharma
* Product Description
* Research and Development
* Product Development Activities
Inodiftagene Vixteplasmid: Anchiano Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
* Comparative Analysis
TAR 200: TARIS Biomedical
* Product Description
* Research and Development
* Product Development Activities
E7766: H3 Biomedicine
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
* Comparative Analysis
UGN-302: UroGen Pharma
* Product Description
* Research and Development
* Product Development Activities
ATX 101: APIM Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix

List of Tables

Table 1 Total Products for Non Muscle Invasive Bladder Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Non Muscle Invasive Bladder Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Lenvatinib Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 130
    According to this study, over the next five years the Lenvatinib market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Lenvatinib business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Lenvatinib market by product type, application, key......
  • Global Levoxyl Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Levoxyl market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Levoxyl business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Levoxyl market by product type, application, key manufact......
  • Global Emergency Contraceptive Pills Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Emergency Contraceptive Pills market will register a 3.2%% CAGR in terms of revenue, the global market size will reach $ 543.7 million by 2025, from $ 478.7 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Emergency Contraceptive Pills business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Emerge......
  • Global Trichomonas Rapid Testing Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 134
    According to this study, over the next five years the Trichomonas Rapid Testing market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Trichomonas Rapid Testing business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Trichomonas Rapid Tes......
  • Global Topical Excipients Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 132
    According to this study, over the next five years the Topical Excipients market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Excipients business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Topical Excipients market by produc......
  • Global Topical Antibiotic Pharmaceuticals Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Topical Antibiotic Pharmaceuticals market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Antibiotic Pharmaceuticals business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Top......
  • Global Tissue-Replacement Products Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 136
    According to this study, over the next five years the Tissue-Replacement Products market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue-Replacement Products business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue-Replacemen......
  • Global Tissue Glue and Bio-adhesive Sealants Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 139
    According to this study, over the next five years the Tissue Glue and Bio-adhesive Sealants market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Glue and Bio-adhesive Sealants business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities ......
  • Global Tissue Culture Reagents Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Tissue Culture Reagents market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Culture Reagents business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue Culture Reagents m......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs